MX9710218A - Compuestos aromaticos y composiciones farmaceuticas que los contienen. - Google Patents
Compuestos aromaticos y composiciones farmaceuticas que los contienen.Info
- Publication number
- MX9710218A MX9710218A MX9710218A MX9710218A MX9710218A MX 9710218 A MX9710218 A MX 9710218A MX 9710218 A MX9710218 A MX 9710218A MX 9710218 A MX9710218 A MX 9710218A MX 9710218 A MX9710218 A MX 9710218A
- Authority
- MX
- Mexico
- Prior art keywords
- optionally substituted
- 3alkyl
- linking group
- ring
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyridine Compounds (AREA)
Abstract
La invencion se relaciona con compuestos de la formula (I), en el que A es un sistema en el anillo opcionalmente sustituido, con la condicion de que los grupos -CH(R3)N(R2)B-R1 y -OR4 sean colocados en una relacion 1,2 a diferentesátomos de carbono en el anillo y el átomo en el anillo colocado de otro al grupo de enlace OR4 (y por lo tanto en la posicion 3 con relacion al grupo de enlace -CH(R3)N(R2)B-R1) no sean sustituidos; B es un sistema en el anillo opcionalmente sustituido; R1 está colocado en el anillo B es como se definio en la especificacion; R2 es hidrogeno, alquilo C1-6, opcionalmente sustituido por hidroxi, ciano o trifluorometilo, alquenilo de C2-6 (no se proporciona el enlace doble en la posicion 1), alquinilo de C2-6 (no se proporciona el enlace triple en la posicion 1), fenil-alquilo de C1-3; R3 es hidrogeno, metilo o etilo; R4 es opcionalmente sustituido; alquilo C1-6; cicloalquilo de C3-7-alquilo de C1-3 o cicloalquilo de C3-7; y oxidos N de -NR2 donde sea posible químicamente; y oxidos S de azufre que contiene anillos donde sea posible químicamente; y sales farmacéuticamente aceptables y ésteres hidrolizables in vivo y amidas de los mismos. Los procesos para su preparacion, intermediarios en su preparacion, su uso como agentes terapéuticos y composiciones farmacéuticas que los contienen.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9512476.4A GB9512476D0 (en) | 1995-06-20 | 1995-06-20 | Aromatic compounds |
GBGB9601462.6A GB9601462D0 (en) | 1996-01-25 | 1996-01-25 | Aromatic compounds |
GBGB9606831.7A GB9606831D0 (en) | 1996-03-30 | 1996-03-30 | Aromatic compounds |
PCT/GB1996/001442 WO1997000863A1 (en) | 1995-06-20 | 1996-06-17 | Aromatic compounds and pharmaceutical compositions containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9710218A true MX9710218A (es) | 1998-03-31 |
Family
ID=27267781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9710218A MX9710218A (es) | 1995-06-20 | 1996-06-17 | Compuestos aromaticos y composiciones farmaceuticas que los contienen. |
Country Status (29)
Country | Link |
---|---|
US (2) | US5994353A (es) |
EP (1) | EP0835246B1 (es) |
JP (1) | JP3949166B2 (es) |
KR (1) | KR19990023006A (es) |
CN (1) | CN1193963A (es) |
AR (1) | AR004495A1 (es) |
AT (1) | ATE207468T1 (es) |
AU (1) | AU700337B2 (es) |
BG (1) | BG63777B1 (es) |
BR (1) | BR9608956A (es) |
CA (1) | CA2220925A1 (es) |
CZ (1) | CZ290923B6 (es) |
DE (1) | DE69616323T2 (es) |
DK (1) | DK0835246T3 (es) |
EE (1) | EE9700341A (es) |
ES (1) | ES2165505T3 (es) |
HR (1) | HRP960288B1 (es) |
HU (1) | HUP9802317A3 (es) |
IL (1) | IL118664A (es) |
MX (1) | MX9710218A (es) |
MY (1) | MY116531A (es) |
NO (1) | NO311129B1 (es) |
NZ (1) | NZ311082A (es) |
PL (1) | PL324205A1 (es) |
PT (1) | PT835246E (es) |
RO (1) | RO119945B1 (es) |
SK (1) | SK282450B6 (es) |
TW (1) | TW434240B (es) |
WO (1) | WO1997000863A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9514160D0 (en) * | 1994-07-25 | 1995-09-13 | Zeneca Ltd | Aromatic compounds |
GB9417532D0 (en) * | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
TW502026B (en) * | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
TW434240B (en) | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
US5834468A (en) | 1995-07-07 | 1998-11-10 | Zeneca Limited | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists |
DE69826286T2 (de) * | 1997-06-27 | 2005-11-24 | Fujisawa Pharmaceutical Co., Ltd. | Derivate mit einem aromatischen ring |
GB9903476D0 (en) * | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Therapeutic agents |
SE0100873D0 (sv) * | 2001-03-13 | 2001-03-13 | Astrazeneca Ab | Method of treatment |
WO2002072145A1 (fr) * | 2001-03-14 | 2002-09-19 | Ono Pharmaceutical Co., Ltd. | Remedes antidepresseurs contenant un antagoniste ep1 en tant que principe actif |
CA2463102C (en) | 2001-10-23 | 2011-05-10 | Applied Research Systems Ars Holding N.V. | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors |
AU2002354056A1 (en) * | 2001-11-19 | 2003-06-10 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary frequency |
JP4554931B2 (ja) | 2001-12-20 | 2010-09-29 | メルク セローノ ソシエテ アノニム | プロスタグランジン調節物質としてのピロリジン誘導体 |
CA2483555A1 (en) | 2002-06-10 | 2003-12-18 | Applied Research Systems Ars Holding N.V. | Gamma lactams as prostaglandin agonists and use thereof |
EP1824819B1 (en) | 2004-12-06 | 2010-01-20 | Merck Serono SA | Pyrrolidin-2-one derivatives for use as dp1 receptor agonists |
AU2005318372A1 (en) | 2004-12-23 | 2006-06-29 | Glaxo Group Limited | Pyridine compounds for the treatment of prostaglandin mediated diseases |
US20060269579A1 (en) * | 2005-05-25 | 2006-11-30 | Musculoskeletal Research Llc | Compositions for treating osteoarthritis |
US7767710B2 (en) | 2005-05-25 | 2010-08-03 | Calosyn Pharma, Inc. | Method for treating osteoarthritis |
RU2452479C2 (ru) | 2007-02-16 | 2012-06-10 | Оно Фармасьютикал Ко., Лтд. | Терапевтический агент при нарушении мочевыделения |
WO2009042854A1 (en) * | 2007-09-26 | 2009-04-02 | Musculoskeletal Research Llc | Ion-channel regulator compositions and methods of using same |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
AP2014007805A0 (en) | 2011-12-28 | 2014-07-31 | Cytokinetics Inc The Regents Of The University Of California | Substituted benzaldehyde compounds and methods fortheir use in increasing tissue oxygenation |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
EA034922B1 (ru) | 2013-03-15 | 2020-04-07 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
ES2864707T3 (es) | 2013-03-15 | 2021-10-14 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de la hemoglobina |
ES2890077T3 (es) | 2013-03-15 | 2022-01-17 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de la hemoglobina |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
BR112015032160B1 (pt) | 2014-02-07 | 2021-11-30 | Global Blood Therapeutics, Inc | Ansolvato cristalino de composto, composição e composição farmacêutica |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
TW201731509A (zh) | 2015-12-04 | 2017-09-16 | 全球血液治療公司 | 針對2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之劑量方案 |
TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
ES2966707T3 (es) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Moduladores de la hemoglobina para el tratamiento de la drepanocitosis |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3632760A (en) * | 1969-06-25 | 1972-01-04 | Merck & Co Inc | Treatment of inflammation |
US3657430A (en) * | 1969-06-25 | 1972-04-18 | Merck & Co Inc | Composition and methods for treating inflammation |
US4350822A (en) * | 1975-03-12 | 1982-09-21 | American Cyanamid Company | Antilipidemicpara-[aryl(alkyl or alkenyl)amino]benzoic acid derivatives |
AU510758B2 (en) * | 1976-01-19 | 1980-07-10 | The Dow Chemical Company | P-benzylaminobenzoic acids |
GB1576007A (en) * | 1976-02-11 | 1980-10-01 | Beecham Group Ltd | Hypolipidaemic compositions |
US4206145A (en) * | 1976-02-11 | 1980-06-03 | Beecham Group Limited | Hypolipidaemic compounds and compositions |
EP0000816A1 (en) * | 1977-08-06 | 1979-02-21 | Beecham Group Plc | Substituted amino-pyridine derivatives, processes for their preparation and pharmaceutical compositions containing them |
US4152452A (en) * | 1977-10-06 | 1979-05-01 | William H. Rorer, Inc. | Method of topically treating inflammation |
DK531479A (da) * | 1979-01-19 | 1980-07-20 | Pfizer | Fremgangsmaade til fremstilling af imidazolderivater og salte deraf |
US4277496A (en) * | 1979-06-04 | 1981-07-07 | Laboratorios Bago S.A. | Methods of treating mammals suffering from inflammation and pain |
US4578390A (en) * | 1981-12-14 | 1986-03-25 | Merck & Co., Inc. | Hydroxybenzylamino derivatives as anti-inflammatory agents |
CA1193598A (en) * | 1982-05-06 | 1985-09-17 | Rafael Foguet | 2-amino-benzoic acid derivatives and processes for their production |
IE56702B1 (en) * | 1982-12-01 | 1991-11-06 | Usv Pharma Corp | Antiinflammatory antiallergic compounds |
US5105017A (en) * | 1983-07-18 | 1992-04-14 | Eli Lilly And Company | Leukotriene antagonist intermediates |
GB8320699D0 (en) * | 1983-08-01 | 1983-09-01 | Wellcome Found | Ethylenediamines |
US4559336A (en) * | 1985-02-25 | 1985-12-17 | G.D. Searle & Co. | 8-Chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-(sulfinyl- and sulfonyl-containing acyl)hydrazides |
US4614617A (en) * | 1985-02-25 | 1986-09-30 | G. D. Searle & Co. | Intermediates for 8-chlorodibenz[(b,f)][1,4]oxazepine-10(11H)-carboxylic acid, 2-(sulfinyl- and sulfonyl-containing acyl)hydrazides |
US4839369A (en) * | 1985-04-16 | 1989-06-13 | Rorer Pharmaceutical Corporation | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments |
US4704386A (en) * | 1985-08-29 | 1987-11-03 | G. D. Searle & Co. | 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[(phenylsulfinyl-, and phenylsulfonyl)alkanoyl]hydrazides |
US4937373A (en) * | 1988-12-08 | 1990-06-26 | Hoffmann-La Roche Inc. | Substituted naphthalene carboxylic acids |
US4897397A (en) * | 1988-12-16 | 1990-01-30 | Schering Corporation | Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents |
DE3903989A1 (de) * | 1989-02-10 | 1990-09-20 | Basf Ag | Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika |
EP0482208B1 (en) * | 1990-04-25 | 2000-07-19 | Nissan Chemical Industries Ltd. | Pyridazinone derivative |
IL99246A0 (en) * | 1990-09-10 | 1992-07-15 | Abbott Lab | Angiotensin ii receptor antagonists and pharmaceutical compositions containing them |
US5250548A (en) * | 1990-09-10 | 1993-10-05 | Abbott Laboratories | Angiotensin II receptor antagonists |
US5284954A (en) * | 1990-09-10 | 1994-02-08 | Abbott Laboratories | Process for the preparation of tetrazoles |
US5210206A (en) * | 1990-09-10 | 1993-05-11 | Abbott Laboratories | 1,3-oxazolyl substituted biphenyl |
GB9021813D0 (en) * | 1990-10-08 | 1990-11-21 | Ici Plc | Tricyclic heterocycles |
CA2102780C (en) * | 1991-05-10 | 2007-01-09 | Alfred P. Spada | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
GB9120640D0 (en) * | 1991-09-27 | 1991-11-06 | Ici Plc | Tricyclic heterocycles |
JPH05230016A (ja) * | 1991-10-14 | 1993-09-07 | Takeda Chem Ind Ltd | アミド誘導体、その製造法および殺菌剤 |
US5324743A (en) * | 1992-12-10 | 1994-06-28 | Eli Lilly And Company | Leukotriene B4 antagonists |
DE4241632A1 (de) * | 1992-12-10 | 1994-06-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US5420270A (en) * | 1993-10-07 | 1995-05-30 | G. D. Searle & Co. | Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
US5441950A (en) * | 1994-06-09 | 1995-08-15 | G. D. Searle & Co. | Substituted dibenzoxazepine and dibenzthiazepine carbamate compounds, pharmaceutical compositions and methods of use |
GB9514160D0 (en) * | 1994-07-25 | 1995-09-13 | Zeneca Ltd | Aromatic compounds |
GB9417532D0 (en) * | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
GB9420557D0 (en) * | 1994-10-12 | 1994-11-30 | Zeneca Ltd | Aromatic compounds |
US5530157A (en) * | 1995-02-16 | 1996-06-25 | Scios Nova Inc. | Anti-inflammatory benzoic acid derivatives |
TW434240B (en) * | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
TW502026B (en) * | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
US5834468A (en) * | 1995-07-07 | 1998-11-10 | Zeneca Limited | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists |
TW454123B (en) | 1999-01-28 | 2001-09-11 | Ibm | Method and system for enabling pervasive computing devices to communicate with each other |
-
1996
- 1996-06-12 TW TW085107056A patent/TW434240B/zh not_active IP Right Cessation
- 1996-06-16 IL IL11866496A patent/IL118664A/en not_active IP Right Cessation
- 1996-06-17 DE DE69616323T patent/DE69616323T2/de not_active Expired - Fee Related
- 1996-06-17 CA CA002220925A patent/CA2220925A1/en not_active Abandoned
- 1996-06-17 AT AT96920936T patent/ATE207468T1/de not_active IP Right Cessation
- 1996-06-17 PT PT96920936T patent/PT835246E/pt unknown
- 1996-06-17 CN CN96196398A patent/CN1193963A/zh active Pending
- 1996-06-17 BR BR9608956A patent/BR9608956A/pt not_active Application Discontinuation
- 1996-06-17 WO PCT/GB1996/001442 patent/WO1997000863A1/en not_active Application Discontinuation
- 1996-06-17 NZ NZ311082A patent/NZ311082A/xx unknown
- 1996-06-17 AU AU62320/96A patent/AU700337B2/en not_active Ceased
- 1996-06-17 ES ES96920936T patent/ES2165505T3/es not_active Expired - Lifetime
- 1996-06-17 MX MX9710218A patent/MX9710218A/es not_active IP Right Cessation
- 1996-06-17 EP EP96920936A patent/EP0835246B1/en not_active Expired - Lifetime
- 1996-06-17 JP JP50365397A patent/JP3949166B2/ja not_active Expired - Fee Related
- 1996-06-17 DK DK96920936T patent/DK0835246T3/da active
- 1996-06-17 KR KR1019970709476A patent/KR19990023006A/ko not_active Application Discontinuation
- 1996-06-17 CZ CZ19974109A patent/CZ290923B6/cs not_active IP Right Cessation
- 1996-06-17 US US08/973,887 patent/US5994353A/en not_active Expired - Fee Related
- 1996-06-17 EE EE9700341A patent/EE9700341A/xx unknown
- 1996-06-17 PL PL96324205A patent/PL324205A1/xx unknown
- 1996-06-17 HU HU9802317A patent/HUP9802317A3/hu unknown
- 1996-06-17 RO RO97-02367A patent/RO119945B1/ro unknown
- 1996-06-17 SK SK1732-97A patent/SK282450B6/sk unknown
- 1996-06-18 MY MYPI96002451A patent/MY116531A/en unknown
- 1996-06-18 HR HR960288A patent/HRP960288B1/xx not_active IP Right Cessation
- 1996-06-20 AR ARP960103226A patent/AR004495A1/es not_active Application Discontinuation
-
1997
- 1997-12-19 NO NO19975985A patent/NO311129B1/no unknown
-
1998
- 1998-01-09 BG BG102173A patent/BG63777B1/bg unknown
-
1999
- 1999-09-13 US US09/395,229 patent/US6365603B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9710218A (es) | Compuestos aromaticos y composiciones farmaceuticas que los contienen. | |
MX9710261A (es) | Compuestos aromaticos y composiciones farmaceuticas que los contienen. | |
MX9606541A (es) | Aminoeteres aromaticos como agentes para aliviar el dolor. | |
TR200003478T2 (tr) | Antikanser maddeleri olarak faydalı izotiyazol türevleri | |
ZA899101B (en) | Quinazolinone derivatives | |
AU8794291A (en) | New oxazolopyridine derivatives, processes for preparing these and pharmaceutical compositions containing them | |
DE59005254D1 (de) | 24-Homo-Vitamin-D-Derivate, Verfahren zu ihrer Herstellung; diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung als Arzneimittel. | |
DE69204662D1 (de) | Poly-4-aminopyrrole-2-carboxamide derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel. | |
ES8405009A1 (es) | Un procedimiento para la preparacion de imidazodiacepinas. | |
GR3020682T3 (en) | Use of dioxabicyclo [3.3.0]octane derivatives for the manufacture of a medicament for inhibiting the metabolism of cholesterol. | |
IE872588L (en) | Compounds | |
ES8403928A1 (es) | Un procedimiento para la preparacion de nuevas macrolidas antibioticas. | |
ES8501410A1 (es) | Un procedimiento para la preparacion de nuevos derivados de fosfolipidos. | |
FI104071B1 (fi) | Analogiamenetelmä terapeuttisesti käyttökelpoisten 2,5-dihydro-2,5-diokso-1H-bents[b]atsepiinijohdannaisten valmistamiseksi | |
ES8604960A1 (es) | Procedimiento para preparar derivados de 1,6-naftiridina | |
ATE86993T1 (de) | Heterotetracyclische laktamderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, die sie enthalten. | |
ATE36154T1 (de) | 4-phenylaminopyridin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel. | |
HUT45059A (en) | Process for producing abeoergoline derivatives | |
ES2010855A6 (es) | Procedimiento de preparacion de derivados de dioxazocina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
HC | Change of company name or juridical status |
Owner name: BIOCOTE LIMITED |
|
PD | Change of proprietorship |
Owner name: ASTRAZENECA UK LIMITED |
|
MM | Annulment or lapse due to non-payment of fees |